Daratumumab in NDMM: Subcutaneous vs IV Formulation

EP: 1.Treatment Options for Patients With MM at First Relapse

EP: 2.A Role for Bispecific Antibodies in R/R MM: Data From MonumenTAL-1 and MajesTEC-1 Studies

EP: 3.How Will Bispecific Antibodies Fit Into the Multiple Myeloma Treatment Paradigm?

EP: 4.Key Takeaways From the ASH 2021 Meeting on Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

EP: 5.Transplant-Eligible NDMM: Updated Results of the GRIFFIN Study

EP: 6.Transplant-Eligible NDMM: Results From the MASTER Study

EP: 7.Triplet or Quadruplet Therapy in Transplant-Ineligible NDMM

Now Viewing

EP: 8.Daratumumab in NDMM: Subcutaneous vs IV Formulation

EP: 9.Relapsed/Refractory MM: Results From the BELLINI Study

EP: 10.Adding Venetoclax to Daratumumab and Dexamethasone in RRMM

EP: 11.ASH 2021: Additional Highlights in Multiple Myeloma

EP: 12.ASH 2021: Key Takeaways for Clinical Practice in Multiple Myeloma

Transcript:

Saad Z. Usmani, MD: The subq [subcutaneous] formulation of daratumumab was approved by the FDA at a very opportune time back in 2020 when we were in the early phases of the COVID-19 pandemic. I think the approval came through in May of 2020. Both patients and physicians saw that as a blessing because the time that the patients were committed to being in the health care setting, being in the infusion center, was rapidly reduced from many hours to 5 minutes or less for the administration of the formulation. Our center had completely gone from IV [intravenous] to subq formulation that year after the regulatory approval came through. It was a good experience for the patients. We did not see any changes in efficacy, not that we expected it, based on the COLUMBA trial and other studies that have incorporated subq daratumumab in all the regimens that were previously approved with the IV formulation. That transition was quite smooth, and it made a lot of patients very happy that we were reducing the time to administer that drug.

Transcript edited for clarity.